Publications by authors named "Charles Inturrisi"

Claim this Profile
N
New Synthesis and Pharmacological Evaluation of Enantiomerically Pure ()- and ()-Methadone Metabolites as -Methyl-d-aspartate Receptor Antagonists.
Marco Banzato, Alberto Furlan, Patrizia Locatelli, Jacopo Sgrignani, Alberto Ongaro, Charles Inturrisi

J Med Chem· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter to the Editor regarding 'Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone'.
Marco Pappagallo, Thomas R Kosten, Charles W Gorodetzky, Frank J Vocci, Frank L Sapienza, Charles E Inturrisi

Mol Psychiatry· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial.
Maurizio Fava, Stephen M Stahl, Luca Pani, Sara De Martin, Andrew J Cutler, Charles E Inturrisi

J Clin Psychiatry· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment.
Nicola Ferri, Sara De Martin, James Stuart, Sergio Traversa, Andrea Mattarei, Charles E Inturrisi

Drugs R D· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug-Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism.
Nicola Ferri, Sara De Martin, James Stuart, Sergio Traversa, Franco Folli, Charles E Inturrisi

Drugs R D· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Should We Use COMM (Current Opioid Misuse Measure) to Screen for Opioid Abuse in Patients With Cancer Pain?
Natalie Moryl, Tito R Mendoza, Susan D Horn, Jelyn C Eustaquio, Charles S Cleeland, Charles Inturrisi

J Natl Compr Canc Netw· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Esmethadone-HCl (REL-1017): a promising rapid antidepressant.
Maurizio Fava, Stephen M Stahl, Sara De Martin, Andrea Mattarei, Ezio Bettini, Charles E Inturrisi

Eur Arch Psychiatry Clin Neurosci· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users.
Megan J Shram, Jack E Henningfield, Glen Apseloff, Charles W Gorodetzky, Sara De Martin, Charles E Inturrisi

Transl Psychiatry· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ca1.3 L-type Ca channel-activated CaMKII/ERK2 pathway in the ventral tegmental area is required for cocaine conditioned place preference.
Arlene Martínez-Rivera, Jin Hao, Richard Rice, Charles E Inturrisi, Anjali M Rajadhyaksha

Neuropharmacology· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosing Prescription Opioid Use Disorder in Patients Using Prescribed Opioids for Chronic Pain.
Deborah S Hasin, Dvora Shmulewitz, Malka Stohl, Eliana Greenstein, Efrat Aharonovich, Charles Inturrisi

Am J Psychiatry· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling.
Stephen M Stahl, Sara De Martin, Andrea Mattarei, Ezio Bettini, Luca Pani, Charles E Inturrisi

Int J Mol Sci· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors.
Ezio Bettini, Stephen M Stahl, Sara De Martin, Andrea Mattarei, Jacopo Sgrignani, Charles E Inturrisi

Pharmaceuticals (Basel)· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
REL-1017 (esmethadone; D-methadone) does not cause reinforcing effect, physical dependence and withdrawal signs in Sprague Dawley rats.
Jack Henningfield, David Gauvin, Francesco Bifari, Reginald Fant, Megan Shram, Charles Inturrisi

Sci Rep· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The N-Methyl-D-Aspartate Receptor Blocker REL-1017 (Esmethadone) Reduces Calcium Influx Induced by Glutamate, Quinolinic Acid, and Gentamicin.
Ezio Bettini, Sara De Martin, Andrea Mattarei, Marco Pappagallo, Stephen M Stahl, Charles E Inturrisi

Pharmaceuticals (Basel)· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial.
Maurizio Fava, Stephen Stahl, Luca Pani, Sara De Martin, Marco Pappagallo, Charles E Inturrisi

Am J Psychiatry· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comment on "Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status".
Marco Pappagallo, Charles E Inturrisi, Paolo L Manfredi

CNS Drugs· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of obesity on pain severity and pain interference.
Jade I Basem, Robert S White, Stephanie A Chen, Elizabeth Mauer, Michele L Steinkamp, Charles E Inturrisi

Pain Manag· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding Opioid Actions, Pain and Analgesia: A Tribute to Dr. Gavril Pasternak.
Kelly M Standifer, Charles E Inturrisi, Kathleen M Foley, Ying-Xian Pan

Cell Mol Neurobiol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
REL-1017 (Esmethadone) Increases Circulating BDNF Levels in Healthy Subjects of a Phase 1 Clinical Study.
Sara De Martin, Daniela Gabbia, Franco Folli, Francesco Bifari, Paolo Fiorina, Charles E Inturrisi

Front Pharmacol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful use of buprenorphine-naloxone medication-assisted program to treat concurrent pain and opioid addiction after cancer therapy.
Natalie Moryl, Alexandra Filkins, Yvona Griffo, Vivek Malhotra, Raina H Jain, Charles Inturrisi

J Opioid Manag· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The N-methyl-D-aspartate receptor antagonist d-methadone acutely improves depressive-like behavior in the forced swim test performance of rats.
Taleen Hanania, Paolo Manfredi, Charles Inturrisi, Ottavio V Vitolo

Exp Clin Psychopharmacol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does transdermal fentanyl work in patients with low BMI? Patient-reported outcomes of pain and percent pain relief in cancer patients on transdermal fentanyl.
Natalie Moryl, Ali Bokhari, Yvona Griffo, Rachel Hadler, Lauren Koranteng, Charles E Inturrisi

Cancer Med· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of the Safety and Pharmacokinetic Profile of D-Methadone, a Novel N-Methyl-D-Aspartate Receptor Antagonist in Healthy, Opioid-Naive Subjects: Results of Two Phase 1 Studies.
Galina Bernstein, Kelly Davis, Catherine Mills, Lu Wang, Michael McDonnell, Charles Inturrisi

J Clin Psychopharmacol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-Reported Outcomes and Opioid Use by Outpatient Cancer Patients.
Natalie Moryl, Vinnidhy Dave, Paul Glare, Ali Bokhari, Vivek T Malhotra, Charles E Inturrisi

J Pain· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis